NEW YORK (GenomeWeb) – By using the CRISPR/Cas9 genome editing approach, researchers from the University of California, San Francisco report that they were able to correct β-thalassemia gene mutations in patient-specific iPS cells.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.